<DOC>
	<DOCNO>NCT01404949</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , treatment two drug leukemia . The first medicine tretinoin ( also call all-trans retinoic acid , ATRA , Vesanoid ) . It approve medicine cause leukemia cell APL mature . It relate vitamin A . The second arsenic trioxide ( Trisenox ) . It approve medicine APL come back earlier treatment . APL often treat tretinoin standard chemotherapy drug . These chemotherapy drug cause infection bleeding . They also damage heart normal bone marrow cell . This lead second leukemia year later . In study , investigator use tretinoin arsenic trioxide together . Both drug work treat APL . They use together limited number people . The investigator want use drug together reduce amount standard chemotherapy decrease side effect . The patient receive standard chemotherapy drug call idarubicin high chance leukemia come back high risk side effect .</brief_summary>
	<brief_title>Combined Tretinoin Arsenic Trioxide Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed Risk-Adapted Postremission Therapy</brief_title>
	<detailed_description>Induction consist tretinoin 45 mg/m2 po daily ( rounded nearest 10mg ) two divide dos ( 25 mg/m2 patient &lt; 20 year age ) 35 day ATO 0.15 mg/kg IV daily 35 dos give 5-7 day per week . The drug discontinue , patient follow clinical complete remission achieve . Idarubicin 12 mg/m2 IV 4 dos added induction day 2 present WBC &gt; 10,000/μl , WBC increase 5,000/μl day 5 , 10,000/μl day 10 , 15,000/μl day 15 , increase risk APL differentiation syndrome relapse patient . Dexamethasone 10 mg twice daily give day 1-14 induction prophylaxis APL differentiation syndrome . All patient receive four course consolidation tretinoin 45 mg/m2 po daily ( rounded nearest 10mg ) ( 25 mg/m2 patient &lt; 20 year age ) 15 day ATO 0.15 mg/kg IV 25 dos . Patients high-risk disease receive Idarubicin Induction may receive intrathecal cytarabine CNS prophylaxis give treat physician consolidation , discretion site PI . High-risk patient also receive maintenance therapy additional course tretinoin ATO every 3 month 2 year . Each maintenance course consist tretinoin 45 mg/m2 po daily ( 25 mg/m2 patient &lt; 20 year age ) 15 day ATO 0.15 mg/kg IV 10 dos . Disease status monitor serial analysis peripheral blood sample use RT-PCR PML-RARα mRNA . Patients follow relapse , death , loss follow-up , removal study . Induction therapy give inpatient outpatient . Consolidation maintenance treatment give outpatient . Consolidation may also give patient 's local institution . Intrathecal cytarabine treatment administer outpatient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Previously untreated patient morphologic diagnosis APL , confirm demonstration ( 15 ; 17 ) use conventional cytogenetics OR florescence situ hybridization ( FISH ) , OR positive RTPCR assay PMLRAR subject 's local institution . Age ≥18 year . Karnofsky performance status ≥ 60 % . Adequate renal function demonstrate serum creatinine ≤ 2.0 mg/dl creatinine clearance &gt; 60 ml/min . Adequate hepatic function demonstrate bilirubin &lt; 2.0 mg/dl ( unless attributable Gilbert 's disease ) alkaline phosphatase , AST , ALT ≤ 2.5 time upper limit normal . Normal cardiac function demonstrate leave ventricular ejection fraction ≥ 50 % echocardiogram MUGA scan . QTc ≤ 500 msec baseline ECG . Negative serum pregnancy test woman childbearing potential . Ability swallow oral medication . Men woman childbearing potential must willing practice effective method birth control treatment least 4 month treatment finish . Patients central nervous system involvement APL eligible may receive concomitant treatment radiation therapy and/or intrathecal chemotherapy accordance standard medical practice . Previous treatment APL , except tretinoin , may give 7 day prior study entry . Active serious infection control antibiotic . Pregnant woman woman breastfeed . Concurrent active malignancy require immediate therapy . Clinically significant cardiac disease ( NY Heart Association Class III IV ) , include chronic arrhythmia , pulmonary disease . Other serious lifethreatening condition deem unacceptable principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Tretinoin</keyword>
	<keyword>all-trans retinoic acid</keyword>
	<keyword>ATRA</keyword>
	<keyword>Vesanoid</keyword>
	<keyword>Arsenic Trioxide</keyword>
	<keyword>ATO</keyword>
	<keyword>Trisenox</keyword>
	<keyword>11-040</keyword>
</DOC>